<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-30265" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Topical Corticosteroids</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Gabros</surname>
            <given-names>Sarah</given-names>
          </name>
          <aff>Rowan University SOM</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Nessel</surname>
            <given-names>Trevor A.</given-names>
          </name>
          <aff>MSU College of Osteopathic Medicine</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Zito</surname>
            <given-names>Patrick M.</given-names>
          </name>
          <aff>University of Miami; Miller School of Medicine</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Sarah Gabros declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Trevor Nessel declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Patrick Zito declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>10</day>
          <month>7</month>
          <year>2023</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-30265.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p content-type="pubmed-excerpt">Topical corticosteroids play a major role in the treatment of many dermatologic conditions. They are FDA-approved and indicated for the use of inflammatory and pruritic presentations of dermatologic conditions. The well-known indications are for diseases such as psoriasis, limited areas of vitiligo, eczema, atopic dermatitis, phimosis, acute radiation dermatitis, lichen planus, lichen simplex chronicus, discoid lupus erythematosus, and lichen sclerosis. They are effective for conditions involving hyper-proliferation, immunological, and inflammatory properties. This activity outlines the indications, mechanism of action, methods of administration, important adverse effects, contraindications, toxicity, and monitoring, of topical corticosteroids so providers can direct patient therapy where they are indicated as part of the interprofessional team.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Identify the three predominant mechanisms of action of topical corticosteroids.</p></list-item><list-item><p>Review the indications for using topical corticosteroids.</p></list-item><list-item><p>Summarize the adverse event profile of topical corticosteroids, as well as contraindications to their use.</p></list-item><list-item><p>Explain the importance of improving care coordination among the interprofessional team to enhance the delivery of care for patients who can benefit from therapy with topical corticosteroids.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=30265&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=30265">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-30265.s2" sec-type="Indications">
        <title>Indications</title>
        <p>Topical corticosteroids play a major role in the treatment of many dermatologic conditions. They are FDA-approved and indicated for the use of inflammatory and pruritic presentations of dermatologic conditions. The well-known indications are for diseases such as psoriasis, limited areas of vitiligo, eczema, atopic dermatitis, phimosis, acute radiation dermatitis, lichen planus, lichen simplex chronicus, discoid lupus erythematosus, and lichen sclerosis.<xref ref-type="bibr" rid="article-30265.r1">[1]</xref> They are effective for conditions involving hyper-proliferation, immunological, and inflammatory properties.<xref ref-type="bibr" rid="article-30265.r2">[2]</xref></p>
      </sec>
      <sec id="article-30265.s3" sec-type="Mechanism of Action">
        <title>Mechanism of Action</title>
        <p>The mechanism of action of topical corticosteroids is vast, consisting of anti-inflammatory, anti-mitotic, and immunosuppressive effects.<xref ref-type="bibr" rid="article-30265.r3">[3]</xref></p>
        <p>The anti-inflammatory effect of topical corticosteroids consists of vasoconstriction, inhibition of the release of phospholipase A2, and a direct inhibitory effect on DNA and inflammatory transcription factors.<xref ref-type="bibr" rid="article-30265.r3">[3]</xref><xref ref-type="bibr" rid="article-30265.r4">[4]</xref>Vasoconstriction of the blood vessels within the upper dermis decreases the number of inflammatory mediators being delivered to the region applied.<xref ref-type="bibr" rid="article-30265.r3">[3]</xref> The anti-inflammatory effect also occurs from the synthesis of lipocortin which inhibits phospholipase A2, ultimately decreasing the production of prostaglandins and leukotrienes.<xref ref-type="bibr" rid="article-30265.r4">[4]</xref>&#x000a0;Topical corticosteroids also act directly at the DNA level to increase the expression of anti-inflammatory genes and indirectly inhibit inflammatory transcription factors, such as NFkb, to decrease the expression of pro-inflammatory genes.<xref ref-type="bibr" rid="article-30265.r3">[3]</xref></p>
        <p>The anti-mitotic effect of topical corticosteroids play a great role in the treatment of psoriasis;&#x000a0;it is proposed that this decrease in epidermal mitosis is secondary to an increase in lipocortin, an endogenous glucocorticoid-regulated protein. An anti-mitotic effect is also present in the dermis which inhibits cell proliferation and collagen synthesis.<xref ref-type="bibr" rid="article-30265.r5">[5]</xref><xref ref-type="bibr" rid="article-30265.r6">[6]</xref></p>
        <p>The immunosuppressive effects of topical corticosteroids involve the inhibition of humoral factors involved in the inflammatory response as well as suppression of the maturation, differentiation, and proliferation of all immune cells.<xref ref-type="bibr" rid="article-30265.r5">[5]</xref></p>
      </sec>
      <sec id="article-30265.s4" sec-type="Administration">
        <title>Administration</title>
        <p>Topical corticosteroids are administered topically; however, successful administration depends upon obtaining an accurate diagnosis, choosing the correct drug, selecting the appropriate&#x000a0;vehicle and potency, and the frequency of application.<xref ref-type="bibr" rid="article-30265.r1">[1]</xref></p>
        <p>The vehicle is the carrier of the drug. The vehicle selection depends on the region affected and the type of&#x000a0;lesion present. It also functions to hydrate the skin and increase absorption. The vehicle options include the following<xref ref-type="bibr" rid="article-30265.r7">[7]</xref>:&#x000a0;</p>
        <list list-type="bullet">
          <list-item>
            <p><italic toggle="yes">Ointments</italic> - administered for thick hyper-keratotic lesions; the most potent vehicle since they are the most occlusive and should not be administered on hair-bearing regions because it may result in folliculitis<xref ref-type="bibr" rid="article-30265.r1">[1]</xref></p>
          </list-item>
          <list-item>
            <p><italic toggle="yes">Creams </italic>- less potent than ointment but cosmetically more appealing since they leave no residue; the drying, non-occlusive nature leads to their administration for acute exudative inflammation and&#x000a0;dermatitis within the intertriginous areas.<xref ref-type="bibr" rid="article-30265.r1">[1]</xref></p>
          </list-item>
          <list-item>
            <p><italic toggle="yes">Lotions </italic>- less occlusive and greasy;&#x000a0;work well in hair-bearing regions</p>
          </list-item>
          <list-item>
            <p><italic toggle="yes">Gels </italic>- like lotions, less&#x000a0;occlusive and greasy;&#x000a0;work well in hair-bearing regions;&#x000a0;more beneficial for the scalp as they do not cause matting of thleast occlusive and greasye hair</p>
          </list-item>
          <list-item>
            <p><italic toggle="yes">Foams </italic>- highly effective for steroid delivery to the scalp but are costly<xref ref-type="bibr" rid="article-30265.r8">[8]</xref>&#x000a0;</p>
          </list-item>
        </list>
        <p>The potency of topical corticosteroids is the amount of drug needed to produce a desired therapeutic effect. The gold standard for determining potency is the vasoconstrictor assay which measures the vasoconstrictive properties based upon cutaneous vasoconstriction.<xref ref-type="bibr" rid="article-30265.r9">[9]</xref> The United States classification consists of seven classes, with class I superpotent and class VII least potent.<xref ref-type="bibr" rid="article-30265.r10">[10]</xref></p>
        <p><italic toggle="yes">Class I</italic>
<italic toggle="yes">superpotent corticosteroids</italic> include clobetasol propionate 0.05% in any vehicle, augmented betamethasone dipropionate 0.05% gel or ointment, diflorasone diacetate 0.05% ointment, fluocinonide 0.1% cream, and halobetasol propionate 0.05% cream or ointment.<xref ref-type="bibr" rid="article-30265.r1">[1]</xref> &#x000a0;&#x000a0;</p>
        <p><italic toggle="yes">Class II</italic>
<italic toggle="yes">high-potency corticosteroids</italic> include amcinonide 0.1% ointment, augmented betamethasone dipropionate 0.05% cream or lotion, betamethasone dipropionate 0.05% ointment, desoximetasone cream or gel or ointment, diflorasone diacetate 0.05% cream, fluocinonide 0.05% cream or gel or ointment, and halcinonide 0.1% cream or ointment or solution.<xref ref-type="bibr" rid="article-30265.r1">[1]</xref></p>
        <p><italic toggle="yes">Class III</italic>
<italic toggle="yes">medium- to high-potency corticosteroids</italic> include amcinonide 0.1% cream, betamethasone dipropionate 0.05% cream, fluticasone propionate 0.005% ointment, and triamcinolone acetonide 0.5% cream or ointment.<xref ref-type="bibr" rid="article-30265.r1">[1]</xref></p>
        <p><italic toggle="yes">Class IV and V medium-potency corticosteroids</italic> include betamethasone valerate 0.1% cream or lotion or foam, desoximetasone 0.05% cream, Fluocinolone acetonide 0.025% cream or ointment, fluticasone propionate 0.05% cream, hydrocortisone butyrate 0.1% ointment, hydrocortisone probutate 0.1% cream, hydrocortisone valerate 0.2% cream or ointment, &#x000a0;&#x000a0;mometasone furoate 0.1% cream or lotion or ointment, triamcinolone acetonide 0.025% cream or lotion or ointment, and triamcinolone acetonide 0.1% cream or lotion or ointment.<xref ref-type="bibr" rid="article-30265.r1">[1]</xref></p>
        <p><italic toggle="yes">Class VI low-potency corticosteroids</italic> include alclometasone dipropionate 0.05% cream or ointment, desonide 0.05% in any vehicle, fluocinolone 0.01% cream, and hydrocortisone butyrate 0.1% cream.<xref ref-type="bibr" rid="article-30265.r1">[1]</xref></p>
        <p><italic toggle="yes">Class VII least-potent corticosteroids</italic> include hydrocortisone 1% and 2.5% cream or lotion or ointment.<xref ref-type="bibr" rid="article-30265.r1">[1]</xref></p>
        <p>Corticosteroids are better absorbed and more permeable in regions of thin epidermis, such as the eyelid, compared to thicker regions of epidermis, such as the sole. The penetration difference between the two varies by 300 fold.<xref ref-type="bibr" rid="article-30265.r11">[11]</xref>The penetration increases two- to ten-fold in diseased states, such as inflammation and desquamation.<xref ref-type="bibr" rid="article-30265.r1">[1]</xref><xref ref-type="bibr" rid="article-30265.r12">[12]</xref>&#x000a0;High-potency steroids are used for the palms and soles, due to the thick stratum corneum, and in nonfacial/nonintertriginous areas for severe dermatoses, such as psoriasis and severe atopic and contact dermatitis. <xref ref-type="bibr" rid="article-30265.r1">[1]</xref>&#x000a0;Medium- to high-potency steroids are useful for regions of thin epidermis and areas of occlusion, such as the eyelid and axilla, respectively.<xref ref-type="bibr" rid="article-30265.r8">[8]</xref> Low-to-medium strength preparations should be used for large surface areas to decrease the risk of systemic absorption. 1917<xref ref-type="bibr" rid="article-30265.r1">[1]</xref></p>
        <p>The amount of steroid used plays a great part in the efficacy of treatment but also in avoiding adverse effects from overuse. One fingertip unit (FTU) is equal to 0.5 grams. The suggested dose of FTU is dependent upon the body region being treated. Topical corticosteroids are recommended for once to twice daily use.<xref ref-type="bibr" rid="article-30265.r13">[13]</xref> A study regarding topical corticosteroid use for atopic dermatitis demonstrated that there was no beneficial evidence to applying topical corticosteroid more than once per day. Applying it more often only resulted in an increase in adverse effects.<xref ref-type="bibr" rid="article-30265.r14">[14]</xref></p>
      </sec>
      <sec id="article-30265.s5" sec-type="Adverse Effects">
        <title>Adverse Effects</title>
        <p>The adverse effects of topical corticosteroids can be divided into local and systemic effects. Local adverse effects occur with prolonged treatment and are based on the topical steroid potency, vehicle, and application site. The most common local effects include atrophy, striae, rosacea, perioral dermatitis, acne, and purpura.<xref ref-type="bibr" rid="article-30265.r6">[6]</xref></p>
        <p>Skin atrophy is the most common adverse effect and occurs due to the anti-mitotic effect of topical corticosteroids.<xref ref-type="bibr" rid="article-30265.r6">[6]</xref> Topical steroid causes the skin to undergo 3 phases: preatrophy, atrophy, and tachyphylaxis. Atrophy occurs when there is a persistent use in the same region. This leads to epidermal thinning and increased resorption within the dermis ground substance. The loss of connective tissue leads to erythema, teleangiectasias, and purpura. Atrophy presents as a burning sensation; the vasoconstrictive effect of the topical corticosteroid relieves the burn.<xref ref-type="bibr" rid="article-30265.r4">[4]</xref> Areas most at risk for atrophy are intertriginous due to thinner skin and increased occlusion. Atrophy is reversible with cessation of steroid use; however, it may take months for the skin to appear normal again.<xref ref-type="bibr" rid="article-30265.r6">[6]</xref></p>
        <p>Tachyphylaxis&#x000a0;is the result of the skin developing tolerance to the topical corticosteroid, which ultimately is a loss of vasoconstriction at the level of the capillaries. It has been demonstrated that the capillaries regain the ability to vasoconstrict after 4 days. For this reason, pulse therapy is recommended and the topical corticosteroid should be discontinued for 4 days if it has lost its effectiveness.<xref ref-type="bibr" rid="article-30265.r13">[13]</xref></p>
        <p>Striae develop due to injury to the dermis and mechanical stress. Inflammation and edema of the dermis results in collagen deposition in the region of the mechanical stress. Striae appear histologically as scars and are permanent.<xref ref-type="bibr" rid="article-30265.r6">[6]</xref></p>
        <p>Topical corticosteroid usage can result in acne formation due to the degradation of the follicular epithelium and an increase in the concentration of free fatty acids on the skin surface. This fosters an environment for bacteria growth, ultimately leading to comedogenesis.<xref ref-type="bibr" rid="article-30265.r6">[6]</xref></p>
        <p>Steroid rosacea can occur when steroids are prescribed initially for erythema with or without pustules. If a low-dose potency topical corticosteroid is prescribed, it can lead to good results until the lesions reappear and higher potency steroid use is continuously needed.<xref ref-type="bibr" rid="article-30265.r6">[6]</xref></p>
        <p>Perioral dermatitis occurs due to prolonged use of potent corticosteroids on the face. It presents as follicular pustules and papules on an erythematous base surround the perioral region but sparing the vermillion border.<xref ref-type="bibr" rid="article-30265.r6">[6]</xref></p>
        <p>Less common local adverse effects include hypertrichosis, pigment alteration, and delayed wound healing. Systemic adverse effects are less likely to occur due to low percutaneous absorption;&#x000a0;however, they can develop with the prolonged use of high-potency steroids on thin epidermal regions. The systemic adverse effects include glaucoma, hypothalamic-pituitary axis suppression, Cushing syndrome, hypertension, and hyperglycemia.<xref ref-type="bibr" rid="article-30265.r6">[6]</xref></p>
      </sec>
      <sec id="article-30265.s6" sec-type="Contraindications">
        <title>Contraindications</title>
        <p>Topical corticosteroids are contraindicated for bacterial infections as their anti-inflammatory and vasoconstrictive effect will mask the infection, ultimately delaying diagnosis and treatment. Topical steroids should also be avoided in impetigo, furuncles and carbuncles, cellulitis, erysipelas, lymphangitis, and erythrasma. Relative contraindications include candida and dermatophytes.<xref ref-type="bibr" rid="article-30265.r15">[15]</xref> The immunosuppressive effects may result in persistent fungal infections that can be identified as tinea incognito, significant for increased spread and inflammation with pustule formation.<xref ref-type="bibr" rid="article-30265.r8">[8]</xref></p>
      </sec>
      <sec id="article-30265.s7" sec-type="Monitoring">
        <title>Monitoring</title>
        <p>Patients need to be monitored carefully as unsupervised use of these medications can result in local and systemic adverse effects. The duration of treatment should not be greater than 2 to 4 weeks, regardless of potency. High-potency steroids should not be administered for a longer than 2 weeks, and after this period, should be tapered to avoid adverse effects.<xref ref-type="bibr" rid="article-30265.r1">[1]</xref><xref ref-type="bibr" rid="article-30265.r13">[13]</xref>&#x000a0;Guidelines to prevent adverse effects include the use of lower-potency steroids, morning-only applications, alternate-day treatment, and decreasing the extent of occlusion.<xref ref-type="bibr" rid="article-30265.r16">[16]</xref></p>
      </sec>
      <sec id="article-30265.s8" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>Topical corticosteroids are one of the most commonly prescribed drugs in dermatology due to the rapid effect of relieving unwanted signs and symptoms. However, if they not properly prescribed or patients are not&#x000a0;given adequate instructions, topical corticosteroid abuse can occur, resulting in adverse effects.<xref ref-type="bibr" rid="article-30265.r17">[17]</xref>&#x000a0;Ideally, dermatologists, nurses, general practitioners, and pharmacists should work together to enforce the way&#x000a0;topical corticosteroids are applied. Realistically, expert advice&#x000a0;is quickly forgotten, and the product label is the only direction that remains. A label stating &#x0201c;apply thinly or use sparingly&#x0201d; promotes anxiety that the product may be dangerous, resulting in poor adherence and treatment. To resolve this matter,&#x000a0;the fingertip unit (FTU) was designed&#x000a0;to make it&#x000a0;easier for practitioners to explain to&#x000a0;patients how much medication should be applied&#x000a0;to different regions of the body. Taking the time to&#x000a0;explain the FTU system can help patients feel confident&#x000a0;that&#x000a0;they are using an adequate amount of steroids. It has also&#x000a0;been recommended&#x000a0;that labels state to "apply enough to cover the&#x000a0;affected&#x000a0;area" and include an image of the fingertip unit and a chart&#x000a0;demonstrating&#x000a0;how many fingertip units should be applied&#x000a0;to each body region so patients will&#x000a0;receive&#x000a0;appropriate&#x000a0;treatment.&#x000a0;Patients should also be advised&#x000a0;not to exceed the prescribed treatment and to only discontinue use under medical supervision. Pharmacists are the last line of healthcare that the patient sees before using the medication and play an important role in enforcing the correct usage and ensuring patient understanding of the interprofessional team's treatment plan.<xref ref-type="bibr" rid="article-30265.r18">[18]</xref></p>
      </sec>
      <sec id="article-30265.s9">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=30265&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=30265">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/30265/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=30265">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <ref-list id="article-30265.s10">
        <title>References</title>
        <ref id="article-30265.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ference</surname>
                <given-names>JD</given-names>
              </name>
              <name>
                <surname>Last</surname>
                <given-names>AR</given-names>
              </name>
            </person-group>
            <article-title>Choosing topical corticosteroids.</article-title>
            <source>Am Fam Physician</source>
            <year>2009</year>
            <month>Jan</month>
            <day>15</day>
            <volume>79</volume>
            <issue>2</issue>
            <fpage>135</fpage>
            <page-range>135-40</page-range>
            <pub-id pub-id-type="pmid">19178066</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30265.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Giannotti</surname>
                <given-names>B</given-names>
              </name>
            </person-group>
            <article-title>Current treatment guidelines for topical corticosteroids.</article-title>
            <source>Drugs</source>
            <year>1988</year>
            <volume>36 Suppl 5</volume>
            <fpage>9</fpage>
            <page-range>9-14</page-range>
            <pub-id pub-id-type="pmid">3076133</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30265.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ahluwalia</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Topical glucocorticoids and the skin--mechanisms of action: an update.</article-title>
            <source>Mediators Inflamm</source>
            <year>1998</year>
            <volume>7</volume>
            <issue>3</issue>
            <fpage>183</fpage>
            <page-range>183-93</page-range>
            <pub-id pub-id-type="pmid">9705606</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30265.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Abraham</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Roga</surname>
                <given-names>G</given-names>
              </name>
            </person-group>
            <article-title>Topical steroid-damaged skin.</article-title>
            <source>Indian J Dermatol</source>
            <year>2014</year>
            <month>Sep</month>
            <volume>59</volume>
            <issue>5</issue>
            <fpage>456</fpage>
            <page-range>456-9</page-range>
            <pub-id pub-id-type="pmid">25284849</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30265.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Uva</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Miguel</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Pinheiro</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Antunes</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Cruz</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Ferreira</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Filipe</surname>
                <given-names>P</given-names>
              </name>
            </person-group>
            <article-title>Mechanisms of action of topical corticosteroids in psoriasis.</article-title>
            <source>Int J Endocrinol</source>
            <year>2012</year>
            <volume>2012</volume>
            <fpage>561018</fpage>
            <pub-id pub-id-type="pmid">23213332</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30265.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Coondoo</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Phiske</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Verma</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Lahiri</surname>
                <given-names>K</given-names>
              </name>
            </person-group>
            <article-title>Side-effects of topical steroids: A long overdue revisit.</article-title>
            <source>Indian Dermatol Online J</source>
            <year>2014</year>
            <month>Oct</month>
            <volume>5</volume>
            <issue>4</issue>
            <fpage>416</fpage>
            <page-range>416-25</page-range>
            <pub-id pub-id-type="pmid">25396122</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30265.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lee</surname>
                <given-names>NP</given-names>
              </name>
              <name>
                <surname>Arriola</surname>
                <given-names>ER</given-names>
              </name>
            </person-group>
            <article-title>Topical corticosteroids: back to basics.</article-title>
            <source>West J Med</source>
            <year>1999</year>
            <season>Nov-Dec</season>
            <volume>171</volume>
            <issue>5-6</issue>
            <fpage>351</fpage>
            <page-range>351-3</page-range>
            <pub-id pub-id-type="pmid">10639873</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30265.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Rathi</surname>
                <given-names>SK</given-names>
              </name>
              <name>
                <surname>D'Souza</surname>
                <given-names>P</given-names>
              </name>
            </person-group>
            <article-title>Rational and ethical use of topical corticosteroids based on safety and efficacy.</article-title>
            <source>Indian J Dermatol</source>
            <year>2012</year>
            <month>Jul</month>
            <volume>57</volume>
            <issue>4</issue>
            <fpage>251</fpage>
            <page-range>251-9</page-range>
            <pub-id pub-id-type="pmid">22837556</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30265.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Goa</surname>
                <given-names>KL</given-names>
              </name>
            </person-group>
            <article-title>Clinical pharmacology and pharmacokinetic properties of topically applied corticosteroids. A review.</article-title>
            <source>Drugs</source>
            <year>1988</year>
            <volume>36 Suppl 5</volume>
            <fpage>51</fpage>
            <page-range>51-61</page-range>
            <pub-id pub-id-type="pmid">3076132</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30265.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Jacob</surname>
                <given-names>SE</given-names>
              </name>
              <name>
                <surname>Steele</surname>
                <given-names>T</given-names>
              </name>
            </person-group>
            <article-title>Corticosteroid classes: a quick reference guide including patch test substances and cross-reactivity.</article-title>
            <source>J Am Acad Dermatol</source>
            <year>2006</year>
            <month>Apr</month>
            <volume>54</volume>
            <issue>4</issue>
            <fpage>723</fpage>
            <page-range>723-7</page-range>
            <pub-id pub-id-type="pmid">16546601</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30265.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Feldmann</surname>
                <given-names>RJ</given-names>
              </name>
              <name>
                <surname>Maibach</surname>
                <given-names>HI</given-names>
              </name>
            </person-group>
            <article-title>Regional variation in percutaneous penetration of 14C cortisol in man.</article-title>
            <source>J Invest Dermatol</source>
            <year>1967</year>
            <month>Feb</month>
            <volume>48</volume>
            <issue>2</issue>
            <fpage>181</fpage>
            <page-range>181-3</page-range>
            <pub-id pub-id-type="pmid">6020682</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30265.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Tadicherla</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Ross</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Shenefelt</surname>
                <given-names>PD</given-names>
              </name>
              <name>
                <surname>Fenske</surname>
                <given-names>NA</given-names>
              </name>
            </person-group>
            <article-title>Topical corticosteroids in dermatology.</article-title>
            <source>J Drugs Dermatol</source>
            <year>2009</year>
            <month>Dec</month>
            <volume>8</volume>
            <issue>12</issue>
            <fpage>1093</fpage>
            <page-range>1093-105</page-range>
            <pub-id pub-id-type="pmid">20027937</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30265.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Drake</surname>
                <given-names>LA</given-names>
              </name>
              <name>
                <surname>Dinehart</surname>
                <given-names>SM</given-names>
              </name>
              <name>
                <surname>Farmer</surname>
                <given-names>ER</given-names>
              </name>
              <name>
                <surname>Goltz</surname>
                <given-names>RW</given-names>
              </name>
              <name>
                <surname>Graham</surname>
                <given-names>GF</given-names>
              </name>
              <name>
                <surname>Hordinsky</surname>
                <given-names>MK</given-names>
              </name>
              <name>
                <surname>Lewis</surname>
                <given-names>CW</given-names>
              </name>
              <name>
                <surname>Pariser</surname>
                <given-names>DM</given-names>
              </name>
              <name>
                <surname>Webster</surname>
                <given-names>SB</given-names>
              </name>
              <name>
                <surname>Whitaker</surname>
                <given-names>DC</given-names>
              </name>
              <name>
                <surname>Butler</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Lowery</surname>
                <given-names>BJ</given-names>
              </name>
              <name>
                <surname>Raimer</surname>
                <given-names>SA</given-names>
              </name>
              <name>
                <surname>Krafchik</surname>
                <given-names>BR</given-names>
              </name>
              <name>
                <surname>Olsen</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Weston</surname>
                <given-names>WL</given-names>
              </name>
            </person-group>
            <article-title>Guidelines of care for the use of topical glucocorticosteroids. American Academy of Dermatology.</article-title>
            <source>J Am Acad Dermatol</source>
            <year>1996</year>
            <month>Oct</month>
            <volume>35</volume>
            <issue>4</issue>
            <fpage>615</fpage>
            <page-range>615-9</page-range>
            <pub-id pub-id-type="pmid">8859293</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30265.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Williams</surname>
                <given-names>HC</given-names>
              </name>
            </person-group>
            <article-title>Established corticosteroid creams should be applied only once daily in patients with atopic eczema.</article-title>
            <source>BMJ</source>
            <year>2007</year>
            <month>Jun</month>
            <day>16</day>
            <volume>334</volume>
            <issue>7606</issue>
            <fpage>1272</fpage>
            <pub-id pub-id-type="pmid">17569936</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30265.r15">
          <label>15</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Cornell</surname>
                <given-names>RC</given-names>
              </name>
            </person-group>
            <article-title>Contraindications for using topical steroids.</article-title>
            <source>West J Med</source>
            <year>1987</year>
            <month>Oct</month>
            <volume>147</volume>
            <issue>4</issue>
            <fpage>459</fpage>
            <page-range>459-60</page-range>
            <pub-id pub-id-type="pmid">18750337</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30265.r16">
          <label>16</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hengge</surname>
                <given-names>UR</given-names>
              </name>
              <name>
                <surname>Ruzicka</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Schwartz</surname>
                <given-names>RA</given-names>
              </name>
              <name>
                <surname>Cork</surname>
                <given-names>MJ</given-names>
              </name>
            </person-group>
            <article-title>Adverse effects of topical glucocorticosteroids.</article-title>
            <source>J Am Acad Dermatol</source>
            <year>2006</year>
            <month>Jan</month>
            <volume>54</volume>
            <issue>1</issue>
            <fpage>1</fpage>
            <page-range>1-15; quiz 16-8</page-range>
            <pub-id pub-id-type="pmid">16384751</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30265.r17">
          <label>17</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Saraswat</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Ethical use of topical corticosteroids.</article-title>
            <source>Indian J Dermatol</source>
            <year>2014</year>
            <month>Sep</month>
            <volume>59</volume>
            <issue>5</issue>
            <fpage>469</fpage>
            <page-range>469-72</page-range>
            <pub-id pub-id-type="pmid">25284852</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30265.r18">
          <label>18</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bewley</surname>
                <given-names>A</given-names>
              </name>
              <collab>Dermatology Working Group</collab>
            </person-group>
            <article-title>Expert consensus: time for a change in the way we advise our patients to use topical corticosteroids.</article-title>
            <source>Br J Dermatol</source>
            <year>2008</year>
            <month>May</month>
            <volume>158</volume>
            <issue>5</issue>
            <fpage>917</fpage>
            <page-range>917-20</page-range>
            <pub-id pub-id-type="pmid">18294314</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
